Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction
- PMID: 22087311
- PMCID: PMC3210169
- DOI: 10.1371/journal.pone.0027416
Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction
Abstract
Background: Tobacco use is associated with an increased prevalence of cardiovascular disease. N-terminal pro-brain natiuretic peptide (NT-proBNP), a widely available biomarker that is associated with cardiovascular outcomes in other conditions, has not been investigated as a predictor of mortality in tobacco smokers. We hypothesized that NT-proBNP would be an independent prognostic marker in a cohort of well-characterized tobacco smokers without known cardiovascular disease.
Methods: Clinical data from 796 subjects enrolled in two prospective tobacco exposed cohorts was assessed to determine factors associated with elevated NT-proBNP and the relationship of these factors and NT-proBNP with mortality.
Results: Subjects were followed for a median of 562 (IQR 252-826) days. Characteristics associated with a NT-proBNP above the median (≥49 pg/mL) were increased age, female gender, and decreased body mass index. By time-to-event analysis, an NT-proBNP above the median (≥49 pg/mL) was a significant predictor of mortality (log rank p = 0.02). By proportional hazard analysis controlling for age, gender, cohort, and severity of airflow obstruction, an elevated NT-proBNP level (≥49 pg/mL) remained an independent predictor of mortality (HR = 2.19, 95% CI 1.07-4.46, p = 0.031).
Conclusions: Elevated NT-proBNP is an independent predictor of mortality in tobacco smokers without known cardiovascular disease, conferring a 2.2 fold increased risk of death. Future studies should assess the ability of this biomarker to guide further diagnostic testing and to direct specific cardiovascular risk reduction inventions that may positively impact quality of life and survival.
Conflict of interest statement
Figures


Similar articles
-
The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.Am Heart J. 2007 Jul;154(1):123-9. doi: 10.1016/j.ahj.2007.04.002. Am Heart J. 2007. PMID: 17584564
-
N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.Catheter Cardiovasc Interv. 2015 Jun;85(7):1240-7. doi: 10.1002/ccd.25788. Epub 2015 Jan 19. Catheter Cardiovasc Interv. 2015. PMID: 25511571
-
The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.Clin Interv Aging. 2016 Feb 16;11:245-53. doi: 10.2147/CIA.S98151. eCollection 2016. Clin Interv Aging. 2016. PMID: 27013868 Free PMC article.
-
N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.JAMA. 2005 Apr 6;293(13):1609-16. doi: 10.1001/jama.293.13.1609. JAMA. 2005. PMID: 15811980
-
Association of NT-proBNP and BNP With Future Clinical Outcomes in Patients With ESKD: A Systematic Review and Meta-analysis.Am J Kidney Dis. 2020 Aug;76(2):233-247. doi: 10.1053/j.ajkd.2019.12.017. Epub 2020 May 6. Am J Kidney Dis. 2020. PMID: 32387090
Cited by
-
Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.Respir Res. 2021 Apr 27;22(1):127. doi: 10.1186/s12931-021-01686-z. Respir Res. 2021. PMID: 33906653 Free PMC article.
-
NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study.Respir Res. 2012 Oct 29;13(1):97. doi: 10.1186/1465-9921-13-97. Respir Res. 2012. PMID: 23107284 Free PMC article.
-
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.Chron Respir Dis. 2017 May;14(2):117-126. doi: 10.1177/1479972316674393. Epub 2016 Dec 15. Chron Respir Dis. 2017. PMID: 27956645 Free PMC article.
-
Elevated plasma level of Pentraxin 3 is associated with emphysema and mortality in smokers.Thorax. 2021 Apr;76(4):335-342. doi: 10.1136/thoraxjnl-2020-215356. Epub 2021 Jan 21. Thorax. 2021. PMID: 33479043 Free PMC article.
-
Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.Am J Physiol Heart Circ Physiol. 2019 Apr 1;316(4):H801-H827. doi: 10.1152/ajpheart.00591.2018. Epub 2019 Feb 1. Am J Physiol Heart Circ Physiol. 2019. PMID: 30707616 Free PMC article. Review.
References
-
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555. - PubMed
-
- Jajich CL, Ostfeld AM, Freeman DH., Jr Smoking and coronary heart disease mortality in the elderly. JAMA. 1984;252:2831–2834. - PubMed
-
- Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647–658. - PubMed
-
- Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials